PositiveID Corporation to Present at the National Investment Banking Association Conference on February 27-28, 2014
February 13 2014 - 8:30AM
PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a
developer of biological detection and diagnostics solutions, today
announced that its Chairman and CEO, William J. Caragol, will
present at the National Investment Banking Association ("NIBA")
Conference on February 27-28, 2014, at the Riverside Hotel in Fort
Lauderdale, FL. The Company's presentation will be posted in the
Investors & Media section of its website.
Mr. Caragol will discuss PositiveID's M-BAND and Firefly
products. M-BAND (Microfluidic Bio-agent Autonomous Networked
Detector) continuously and autonomously analyzes air samples for
the detection of biological airborne threats in the form of
bacteria, viruses, and toxins. The technology was developed under
contract with the "DHS" Science & Technology directorate, which
included $30 million of contract funding. M-BAND is designed to
detect the release of pathogens into the air as part of a defense
against potential terrorist attacks.
Firefly Dx is a point-of-need, handheld system designed to
deliver molecular diagnostic results using real-time TaqMan® PCR
(polymerase chain reaction) chemistry. Firefly is being developed
to meet the growing need in healthcare and molecular diagnostics
markets for more rapid and accurate point-of-need diagnostics that
will enable hospitals, physicians and other providers to save
lives. Firefly can derive results from a sample in less than 20
minutes, at the point of need, compared to two to four hours for a
lab device, which would enable accurate diagnostics leading to more
rapid and effective treatment than what is currently available with
existing systems.
About NIBA
The National Investment Banking Association (NIBA) is the only
not-for-profit association for national, regional and independent
broker dealers, investment banking firms, investment advisors, and
related capital market service providers. Its member firms:
are responsible for 90 percent of all IPO's under $20 million; have
successfully completed more than 1,000 equity offerings; have
raised over $10 billion in new capital for emerging growth
companies; represent more than 8,800 registered representatives;
have more than $76 billion in assets under management; and
represent more than 60 key industry services. For more
information, visit http://nibanet.org/.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and
developer of biological detection systems for America's homeland
defense industry as well as rapid biological testing. PositiveID is
focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in
order to detect biological threats and analyze biological samples.
For more information on PositiveID, please visit
http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations including,
without limitation, the likelihood that Firefly is being developed
to meet the growing need in healthcare and molecular diagnostics
markets for more rapid and accurate point-of-need diagnostics that
will enable hospitals, physicians and other providers to save
lives; the likelihood that Firefly would enable accurate
diagnostics leading to more rapid and effective treatment than what
is currently available with existing systems; constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and
PositiveID's actual results could differ materially from expected
results. Additional information about these and other factors that
could affect the Company's business is set forth in the Company's
various filings with the Securities and Exchange Commission,
including those set forth in the Company's 10-K filed on April 16,
2013, and 10-Q filed on May 20, 2013, under the caption "Risk
Factors." The Company undertakes no obligation to update or release
any revisions to these forward-looking statements to reflect events
or circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by law.
CONTACT: PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com